Vitae Pharmaceuticals Company Profile (NASDAQ:VTAE)

About Vitae Pharmaceuticals

Vitae Pharmaceuticals logoVitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company's product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer's disease, or Alzheimer's. VTP-43742, the Company's wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VTAE
  • CUSIP:
Key Metrics:
  • Previous Close: $21.00
  • 50 Day Moving Average: $18.81
  • 200 Day Moving Average: $11.50
  • 52-Week Range: $4.08 - $21.03
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.35
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Beta: 0.62
  • Net Margins: -13,954.35%
  • Return on Equity: -65.51%
  • Return on Assets: -59.63%
  • Current Ratio: 12.83%
  • Quick Ratio: 12.83%
Additional Links:
Companies Related to Vitae Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Vitae Pharmaceuticals (NASDAQ:VTAE) (?)
Ratings Breakdown: 6 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $21.67 (3.17% upside)

Analysts' Ratings History for Vitae Pharmaceuticals (NASDAQ:VTAE)
DateFirmActionRatingPrice TargetDetails
9/20/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralView Rating Details
9/15/2016BMO Capital MarketsDowngradeOutperform -> Market Perform$17.00 -> $21.00View Rating Details
9/14/2016WedbushDowngradeOutperform -> Neutral$21.00 -> $23.00View Rating Details
9/14/2016Stifel NicolausDowngradeBuy -> Hold$21.00View Rating Details
9/11/2016Wells Fargo & CompanyDowngradeOutperform -> Market PerformView Rating Details
8/4/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
(Data available from 2/22/2015 forward)


Earnings History for Vitae Pharmaceuticals (NASDAQ:VTAE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2016Q2($0.41)($0.36)ViewListenView Earnings Details
5/10/2016Q1($0.51)($0.44)$0.05 millionViewListenView Earnings Details
3/3/2016Q415($0.62)($0.52)$0.14 million$0.09 millionViewListenView Earnings Details
11/5/2015Q315($0.48)($0.60)$0.18 million$0.18 millionViewListenView Earnings Details
8/4/2015Q215($0.45)($0.45)$0.09 million$0.16 millionViewListenView Earnings Details
5/13/2015Q115($0.33)($0.47)$0.08 millionViewListenView Earnings Details
3/31/2015Q414($0.45)($0.40)$0.19 million$0.16 millionViewListenView Earnings Details
11/12/2014Q3($0.13)($1.03)$6.39 million$6.18 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Vitae Pharmaceuticals (NASDAQ:VTAE)
Current Year EPS Consensus Estimate: $-1.66 EPS
Next Year EPS Consensus Estimate: $-1.85 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.39)($0.39)($0.39)
Q2 20161($0.35)($0.35)($0.35)
Q3 20161($0.35)($0.35)($0.35)
Q4 20161($0.34)($0.34)($0.34)
Q1 20171($0.34)($0.34)($0.34)
Q2 20171($0.34)($0.34)($0.34)
Q3 20171($0.32)($0.32)($0.32)
Q4 20171($0.29)($0.29)($0.29)
(Data provided by Zacks Investment Research)


Dividend History for Vitae Pharmaceuticals (NASDAQ:VTAE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Vitae Pharmaceuticals (NASDAQ:VTAE)
Insider Ownership Percentage: 14.80%
Institutional Ownership Percentage: 72.58%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/14/2016Adage Capital Partners Gp, L.LMajor ShareholderSell1,025,000$20.85$21,371,250.00View SEC Filing  
9/14/2016Jeffrey S HatfieldCEOSell50,000$20.81$1,040,500.00View SEC Filing  
3/21/2016Donald J Hayden JrDirectorSell16,130$7.42$119,684.60View SEC Filing  
12/29/2015Donald J. Hayden, Jr.DirectorSell16,130$18.00$290,340.00View SEC Filing  
12/23/2015Jeffrey S. HatfieldCEOSell22,524$17.00$382,908.00View SEC Filing  
9/21/2015Donald J. Hayden, Jr.DirectorSell16,130$17.00$274,210.00View SEC Filing  
9/29/2014Peter BarrettDirectorBuy37,500$8.00$300,000.00View SEC Filing  
9/29/2014Venrock Management Iii LlcMajor ShareholderBuy772,333$8.00$6,178,664.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Vitae Pharmaceuticals (NASDAQ:VTAE)
News IconIs The Sell-Side Predicting That Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Will Move Higher? - Winfield Review (NASDAQ:VTAE) - February 17 at 6:59 AM
News IconVitae Pharmaceuticals Inc VTAE Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 19122016] Prices from USD $250 (NASDAQ:VTAE) - February 7 at 8:40 PM
News IconAnacor, Ziarco…could Realm be the next hot property in dermatology? - The Pharma Letter (registration) (NASDAQ:VTAE) - February 2 at 6:39 AM
News IconEarnings in Full Force, Analysts Take Aim at Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Wall Street Beacon (NASDAQ:VTAE) - January 27 at 3:49 PM
News IconStock Perspective: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Earnings in View - Aiken Advocate (NASDAQ:VTAE) - January 19 at 4:02 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Wall Street Beacon (NASDAQ:VTAE) - January 18 at 3:46 PM
News IconWill The Needle Move For Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:VTAE) - January 13 at 5:45 AM logoAllergan Shifts Strategy to Focus on Growth - (NASDAQ:VTAE) - January 11 at 3:32 PM logoAllergan to Veer Toward Accretive M&A - (NASDAQ:VTAE) - January 10 at 9:06 PM logoAllergan: You Can't Be Negative On This One (NASDAQ:VTAE) - December 21 at 3:31 PM logo4 Reasons To Buy Allergan (NASDAQ:VTAE) - November 28 at 10:38 AM
News IconVitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Under Analyst Spotlight - UK Market News (NASDAQ:VTAE) - November 25 at 8:00 AM
News IconWhat are Analysts Expecting for Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Earnings? - CSZ News (NASDAQ:VTAE) - November 16 at 8:34 PM
News IconNew Analyst Ratings On Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - NewsDen (NASDAQ:VTAE) - November 13 at 12:01 PM logo$690M done deal: Allergan completes Vitae acquisition (NASDAQ:VTAE) - November 11 at 8:02 PM
News IconVitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Analyst Review - NewsDen (NASDAQ:VTAE) - November 10 at 12:00 PM
News IconAnalysts Take: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Projected Earnings & Price Targets - CSZ News (NASDAQ:VTAE) - November 2 at 8:48 PM logoVITAE PHARMACEUTICALS, INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisit (NASDAQ:VTAE) - October 25 at 8:07 PM
News IconInsiders are Scaling Back Holdings in Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - CSZ News (NASDAQ:VTAE) - October 18 at 7:52 PM logoAllergan, Vitae Pharma Announce Expiration Of HSR Waiting Period - Quick Facts (NASDAQ:VTAE) - October 17 at 7:53 PM
News IconRecently Changed Price Targets On Vitae Pharmaceuticals, Inc ... - NewsDen (NASDAQ:VTAE) - October 16 at 7:46 PM
News IconInsiders are Curtailing Holdings in Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - CSZ News (NASDAQ:VTAE) - October 11 at 6:49 AM logoVitae Pharmaceuticals, Inc. (NASDAQ:VTAE):Stock Price Estimate At $18.8 - Investor Newswire (NASDAQ:VTAE) - October 1 at 6:58 PM
News IconRecent Investment Analysts' Ratings Updates for Vitae Pharmaceuticals (VTAE) - Evergreen Investor (NASDAQ:VTAE) - September 30 at 7:27 AM
News IconInvestor News: Buyout of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) under Investigation (NASDAQ:VTAE) - September 28 at 7:47 PM
News IconInvestor News: Buyout of Vitae Pharmaceuticals Inc (NASDAQ:VTAE ... - GroundReport (NASDAQ:VTAE) - September 28 at 7:27 AM logoVITAE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces ... - PR Newswire (press release) (NASDAQ:VTAE) - September 25 at 6:58 AM logoVITAE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Vitae Pharmaceuticals, … (NASDAQ:VTAE) - September 24 at 6:56 AM
News IconHC Stocks Outlines! Vitae Pharmaceuticals Inc (VTAE), Great Basin ... - share market updates (press release) (NASDAQ:VTAE) - September 23 at 7:22 PM logoAllergan's Vitae buy could spark more interest in Kadmon (NASDAQ:VTAE) - September 23 at 6:49 AM
News IconHC Stocks Outlines! Baxter International Inc (BAX), Vitae ... - share market updates (press release) (NASDAQ:VTAE) - September 21 at 11:53 AM
News IconHC Stocks Indications! Apricus Biosciences Inc (APRI), Vitae Pharmaceuticals Inc (NASDAQ:VTAE) - share market updates (press release) (NASDAQ:VTAE) - September 21 at 11:53 AM logoAllergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma - Benzinga (NASDAQ:VTAE) - September 21 at 11:53 AM logoAcquisition of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) Under Investigation for Investors (NASDAQ:VTAE) - September 19 at 7:55 PM
News IconHC Stocks Growth= Apricus Biosciences Inc (NASDAQ:APRI), Vitae ... - share market updates (press release) (NASDAQ:VTAE) - September 16 at 7:43 PM logoVitae Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VTAE) : September 16, 2016 (NASDAQ:VTAE) - September 16 at 7:43 PM
News IconWhat are Analyst Opinions for Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Newburg Press (NASDAQ:VTAE) - September 16 at 11:41 AM


What is Vitae Pharmaceuticals' stock symbol?

Vitae Pharmaceuticals trades on the NASDAQ under the ticker symbol "VTAE."

Where is Vitae Pharmaceuticals' stock going? Where will Vitae Pharmaceuticals' stock price be in 2017?

6 analysts have issued 12-month price targets for Vitae Pharmaceuticals' stock. Their forecasts range from $21.00 to $23.00. On average, they expect Vitae Pharmaceuticals' stock price to reach $21.67 in the next twelve months.

When will Vitae Pharmaceuticals announce their earnings?

Vitae Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November, 3rd 2016.

How do I buy Vitae Pharmaceuticals stock?

Shares of Vitae Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Vitae Pharmaceuticals stock cost?

One share of Vitae Pharmaceuticals stock can currently be purchased for approximately $21.00.

Vitae Pharmaceuticals (NASDAQ:VTAE) Chart for Wednesday, February, 22, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Vitae Pharmaceuticals (NASDAQ:VTAE)

Earnings History Chart

Earnings by Quarter for Vitae Pharmaceuticals (NASDAQ:VTAE)

Dividend History Chart

Dividend Payments by Quarter for Vitae Pharmaceuticals (NASDAQ:VTAE)

Last Updated on 2/22/2017 by Staff